ДЕМОПУЛОС Грегори А. (US),ГАИТАНАРИС Джордж А. (US)
申请号：
RU2013126476/15
公开号：
RU2013126476A
申请日:
2011.11.07
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. An agent that inhibits phosphodiesterase 7 (PDE7) for use in treating or reducing the likelihood of dependence, which is dependence on the substance causing the dependence, or which is the practice of addictive or obsessive behavior associated with primary impulse disorder or obsessive-compulsive disorder, where defined that the patient is at risk of developing addiction； and the patient is administered an amount of a phosphodiesterase 7 inhibitor (PDE7) effective to treat or reduce the likelihood of dependence. 2. The use according to claim 1, wherein the patient is dependent on an addictive agent selected from the group including: alcohol, nicotine, marijuana, marijuana derivatives, an opioid agonist, benzodiazepine, barbiturate and a psychostimulant. 3. The use according to claim 1, wherein the addiction is addictive or compulsive behavior associated with a primary impulse disorder or obsessive-compulsive disorder selected from the group including: compulsive overeating, gambling, pathological use of electronic devices, pathological use of electronic video games, pathological use of electronic communication devices, abnormal use of cell phones, pornography addiction, sexual addiction, obsessive Ratu money, anorexia, bulimia, episodic syndrome disorders control kleptomaniiyu, pyromania, trichotillomania, compulsive exercise and compulsive pererabotku.4. The use according to any one of paragraphs. 1-3, where the patient has previously reduced or eliminated the use of an addictive agent or practice1. Агент, ингибирующий фосфодиэстеразу 7 (ФДЭ7) для применения в лечении или снижении вероятности зависимости, которая является зависимостью от вещества, вызывающего зависимость, или которая является практикой аддиктивного или навязчивого поведения, связанного с первичным расстройством побуждений или обсессивно-компульсивным расстройством, где определено, что пациент подвержен риску развития зависимости； и пациенту вводят количество ингибитора фосфодиэстеразы 7 (ФДЭ7),
